RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
In previous research arachidonylethanolamide (anandamide) has been shown to produce behavioral effects in mice characteristic of psychoactive cannabinoids, including antinociception, catalepsy, hypothermia, and hypomotility. However, differences have also been found between anandamide and Delta(9)-tetrahy- drocannabinol (Delta(9)-THC), with anandamide having lower potency, a more rapid onset, and shorter duration of action than Delta(9)-THC. Although it can produce Delta(9)-THC-like discriminative stimulus effects in rats, anandamide also produces concomitant response rate decreasing effects, whereas with Delta(9)-THC there is a better separation of these two behavioral effects. The present study was designed to examine the discriminative stimulus effects of anandamide in rhesus monkeys trained to discriminate Delta(9)-THC from vehicle. While anandamide failed to produce reliable substitution for Delta(9)-THC and did not reduce response rates at doses up to 10 mg/kg, 2-methylarachidonyl-2'-fluoroethylamide (methylated fluoroanadamide), a putative stable analog of anandamide, produced full dose-dependent substitution for Delta(9)-THC at doses that caused no significant changes in response rates. These results suggest that systemically administered anandamide may be metabolized in monkeys before behaviorally active concentrations could reach the brain and further suggest that the metabolically more stable analog of anandamide, methylated fluoroanandamide, may aid in the discovery of functional properties of the endogenous cannabinoid system. (C) 1997 Elsevier Science Inc